메뉴 건너뛰기




Volumn 63, Issue 3, 2008, Pages 152-169

Multiorgan-protective actions of blockers of the renin-angiotensin system, statins and erythropoietin: Common pleiotropic effects in reno-, cardio- and neuroprotection

Author keywords

ACE inhibition; Erythropoietin; Multi organ protection; Pleiotropic effects; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CANDESARTAN; CAPTOPRIL; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPOSARTAN; ERYTHROPOIETIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; MEVINOLIN; NIFEDIPINE; PERINDOPRIL; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

EID: 47949084299     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2008.026     Document Type: Review
Times cited : (5)

References (141)
  • 1
    • 13844272275 scopus 로고    scopus 로고
    • Multi-organ protection and the kidney. From nephroprotection, cardioprotection, neuroprotection to multi-organ protection
    • Gluhovschi Gh, Bozdog Gh, Petrica L, et al. Multi-organ protection and the kidney. From nephroprotection, cardioprotection, neuroprotection to multi-organ protection. Nefrologia (Madrid, Spain) 2004; Vol XXIV, 519-35.
    • (2004) Nefrologia (Madrid, Spain) , vol.24 , pp. 519-535
    • Gluhovschi, G.1    Bozdog, G.2    Petrica, L.3
  • 2
    • 0141563596 scopus 로고    scopus 로고
    • The history and future of nephroprotection
    • Brenner BM. The history and future of nephroprotection. Kidney Int 2003, 64 (4): 1163.
    • (2003) Kidney Int , vol.64 , Issue.4 , pp. 1163
    • Brenner, B.M.1
  • 3
    • 0032512094 scopus 로고    scopus 로고
    • Pathophysiology of progressive nephropathies
    • Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339 (20): 1448-56.
    • (1998) N Engl J Med , vol.339 , Issue.20 , pp. 1448-1456
    • Remuzzi, G.1    Bertani, T.2
  • 4
    • 0345376885 scopus 로고    scopus 로고
    • The future of renoprotection: Frustration and promises
    • Schieppati A, Remuzzi G. The future of renoprotection: frustration and promises. Kidney Int 2003; 64(6): 1947-55.
    • (2003) Kidney Int , vol.64 , Issue.6 , pp. 1947-1955
    • Schieppati, A.1    Remuzzi, G.2
  • 5
    • 0037048886 scopus 로고    scopus 로고
    • The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure
    • Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D. The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure. Presse Med 2002; 31,36, 1714-20
    • (2002) Presse Med , vol.31 , Issue.36 , pp. 1714-1720
    • Bernadet-Monrozies, P.1    Rostaing, L.2    Kamar, N.3    Durand, D.4
  • 6
    • 33745515438 scopus 로고    scopus 로고
    • Angiotensin receptor blockers and cerebral protection in stroke
    • Thone- Reineke C, Steckelings UM, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl 2006; 24:115-21.
    • (2006) J Hypertens Suppl , vol.24 , pp. 115-121
    • Thone- Reineke, C.1    Steckelings, U.M.2    Unger, T.3
  • 7
    • 0028867804 scopus 로고
    • Role of cardiac renin-angiotensin system in hypertensive heart disease
    • Holmer SR, Riegger GA. Role of cardiac renin-angiotensin system in hypertensive heart disease. Herz 1995; 20: 322-9.
    • (1995) Herz , vol.20 , pp. 322-329
    • Holmer, S.R.1    Riegger, G.A.2
  • 8
    • 18544369738 scopus 로고    scopus 로고
    • The cardiovascular continuum and renin-angiotensin-aldosterone system blockade
    • Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005; 23(1): S9-17.
    • (2005) J Hypertens Suppl , vol.23 , Issue.1
    • Dzau, V.1
  • 9
    • 0036672123 scopus 로고    scopus 로고
    • The renin-angiotensin system in the brain: Possible therapeutic implications for AT(1)-receptor blockers
    • Culman J, Blume A, Gohlke P, Unger T. The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers. J Hum Hypertens 2002;16 Suppl 3: S64-70.
    • (2002) J Hum Hypertens , vol.16 , Issue.SUPPL. 3
    • Culman, J.1    Blume, A.2    Gohlke, P.3    Unger, T.4
  • 10
    • 20844454491 scopus 로고    scopus 로고
    • Dual blockade of the reninangiotensin system: The ultimate treatment for renal protection?
    • Codreanu I, Perico N, Remuzzi G. Dual blockade of the reninangiotensin system: the ultimate treatment for renal protection? J Am Soc Nephrol 2005;16 Suppl 1:S34-8.
    • (2005) J Am Soc Nephrol , vol.16 , Issue.SUPPL. 1
    • Codreanu, I.1    Perico, N.2    Remuzzi, G.3
  • 11
    • 0033936063 scopus 로고    scopus 로고
    • Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers
    • Jul;
    • Weir MR, Henrich WL. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens 2000 Jul;9(4):403-11.
    • (2000) Curr Opin Nephrol Hypertens , vol.9 , Issue.4 , pp. 403-411
    • Weir, M.R.1    Henrich, W.L.2
  • 12
    • 33846973650 scopus 로고    scopus 로고
    • Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease
    • Ferrari P. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. Nephrology (Carlton) 2007; 12: 81-9.
    • (2007) Nephrology (Carlton) , vol.12 , pp. 81-89
    • Ferrari, P.1
  • 13
    • 28544433872 scopus 로고    scopus 로고
    • Preserving cardiac function in the hypertensive patient why renal parameters hold the key
    • Montalescot G, Collet JP. Preserving cardiac function in the hypertensive patient why renal parameters hold the key. Eur heart J 2005; 26: 2616-22.
    • (2005) Eur heart J , vol.26 , pp. 2616-2622
    • Montalescot, G.1    Collet, J.P.2
  • 14
    • 28044445114 scopus 로고    scopus 로고
    • Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies
    • Dec 1;
    • Carr AA, Kowey PR, Devereux RB, et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005 Dec 1; 96(11): 1530-6.
    • (2005) Am J Cardiol , vol.96 , Issue.11 , pp. 1530-1536
    • Carr, A.A.1    Kowey, P.R.2    Devereux, R.B.3
  • 15
    • 0036022891 scopus 로고    scopus 로고
    • The role of angiotensin II antagonist in type 2 diabetes mellitus: A review of renoprotection tudy
    • Zanella MT, Ribeiro AB. The role of angiotensin II antagonist in type 2 diabetes mellitus: a review of renoprotection tudy. Clin Ther 2002; 24: 1019-34.
    • (2002) Clin Ther , vol.24 , pp. 1019-1034
    • Zanella, M.T.1    Ribeiro, A.B.2
  • 16
    • 13844250946 scopus 로고    scopus 로고
    • Renal-, cardiac- and cerebroprotective effects of Perindopril in patients with primary chronic glomerulonephritis
    • Petrica L, Petrica M, Bob F, et al. Renal-, cardiac- and cerebroprotective effects of Perindopril in patients with primary chronic glomerulonephritis. Nefrologia 2003; 8: 71.
    • (2003) Nefrologia , vol.8 , pp. 71
    • Petrica, L.1    Petrica, M.2    Bob, F.3
  • 17
    • 0028767329 scopus 로고
    • Trandolaprils protective effects in stroke-prone spontaneously hypertensive rats persist long after treatment withdrawal
    • Apr 7;
    • Richer C, Fornes P, Vacher E, et al. Trandolaprils protective effects in stroke-prone spontaneously hypertensive rats persist long after treatment withdrawal. Am J Cardiol 1994 Apr 7;73(10):26C-35C.
    • (1994) Am J Cardiol , vol.73 , Issue.10
    • Richer, C.1    Fornes, P.2    Vacher, E.3
  • 18
    • 0027445866 scopus 로고
    • Quinapril prevents stroke both during and after the treatment period in stroke-prone spontaneously hypertensive rats
    • Nov;
    • Vacher E, Fornes P, Domergue V, et al. Quinapril prevents stroke both during and after the treatment period in stroke-prone spontaneously hypertensive rats. Am J Hypertens 1993 Nov;6(11 Pt 1):951-9.
    • (1993) Am J Hypertens , vol.6 , Issue.11 PART 1 , pp. 951-959
    • Vacher, E.1    Fornes, P.2    Domergue, V.3
  • 20
    • 2142773128 scopus 로고    scopus 로고
    • Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy
    • Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J 2004;18(7):805-15.
    • (2004) FASEB J , vol.18 , Issue.7 , pp. 805-815
    • Danesh, F.R.1    Kanwar, Y.S.2
  • 21
    • 0037131289 scopus 로고    scopus 로고
    • Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury
    • Mason JC, Ahmed Z, Mankoff R, et al. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Cir Res 2002; 91: 696-703.
    • (2002) Cir Res , vol.91 , pp. 696-703
    • Mason, J.C.1    Ahmed, Z.2    Mankoff, R.3
  • 22
    • 32244446516 scopus 로고    scopus 로고
    • HMG-CoA reductase inhibitors in chronic heart failure: Potential mechanisms of benefit and risk
    • Laufs U, Custodis F, Bohm M. HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk. Drugs 2006;66(2):145-54.
    • (2006) Drugs , vol.66 , Issue.2 , pp. 145-154
    • Laufs, U.1    Custodis, F.2    Bohm, M.3
  • 23
    • 34247869755 scopus 로고    scopus 로고
    • Statins attenuate ischemia reperfusion injury by inducing hemo oxygenase-1 in infiltrating macrophages
    • Gueler F, Park JK, Rong S, et al. Statins attenuate ischemia reperfusion injury by inducing hemo oxygenase-1 in infiltrating macrophages. Am J Pathol 2007; 170: 1192-9.
    • (2007) Am J Pathol , vol.170 , pp. 1192-1199
    • Gueler, F.1    Park, J.K.2    Rong, S.3
  • 24
  • 25
    • 33645471375 scopus 로고    scopus 로고
    • Statins and renal diseases: From primary prevention to renal replacement therapy
    • D'Amico G. Statins and renal diseases: from primary prevention to renal replacement therapy. J Am Soc Nephrol 2006; 17(Suppl2) S148-S52.
    • (2006) J Am Soc Nephrol , vol.17 , Issue.SUPPL.2
    • D'Amico, G.1
  • 26
    • 33344466350 scopus 로고    scopus 로고
    • Low high-density lipoprotein cholesterol and cardiovascular disease: Risk reduction with statin therapy
    • Rosenson RS. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J 2006;151(3):556-63.
    • (2006) Am Heart J , vol.151 , Issue.3 , pp. 556-563
    • Rosenson, R.S.1
  • 27
    • 12844260208 scopus 로고    scopus 로고
    • Atorvastatin induction on VEGF and BDNF promotes brain plasticity after stroke in mice
    • Chen J, Zhang C, Jiang H, et al. Atorvastatin induction on VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab 2005; 25: 281-90.
    • (2005) J Cereb Blood Flow Metab , vol.25 , pp. 281-290
    • Chen, J.1    Zhang, C.2    Jiang, H.3
  • 28
    • 33748852247 scopus 로고    scopus 로고
    • Hypothesis: The antitunor activities of statins may be mediated by IL-18
    • Takahashi HK, Weitz-Schmidt G, Iwagaki H, et al. Hypothesis: the antitunor activities of statins may be mediated by IL-18. J Leukoc Biol 2006; 80: 215-6.
    • (2006) J Leukoc Biol , vol.80 , pp. 215-216
    • Takahashi, H.K.1    Weitz-Schmidt, G.2    Iwagaki, H.3
  • 29
    • 34249987651 scopus 로고    scopus 로고
    • HMG-CoA reductase inhibitors and the kidney
    • Campese VM, Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int 2007; 71:1215-22.
    • (2007) Kidney Int , vol.71 , pp. 1215-1222
    • Campese, V.M.1    Park, J.2
  • 30
    • 27144534466 scopus 로고    scopus 로고
    • Effect of xxxx on C-reactive protein and renal function in patients with chronic kidney disease
    • Verma A, Ranganna KM, Reddy RS, Verma M, Gordon N. Effect of xxxx on C-reactive protein and renal function in patients with chronic kidney disease. J Am Cardiol 2005; 96: 1290-2.
    • (2005) J Am Cardiol , vol.96 , pp. 1290-1292
    • Verma, A.1    Ranganna, K.M.2    Reddy, R.S.3    Verma, M.4    Gordon, N.5
  • 31
    • 33745847843 scopus 로고    scopus 로고
    • Drug insight: Immunomodulatory effects of statins- potential benefits for renal patients
    • Steffens S, Mach F. Drug insight: immunomodulatory effects of statins- potential benefits for renal patients. Nat Clin Pract Nephrol 2006, 2: 378-87.
    • (2006) Nat Clin Pract Nephrol , vol.2 , pp. 378-387
    • Steffens, S.1    Mach, F.2
  • 32
    • 0034910647 scopus 로고    scopus 로고
    • The effects of lipid-lowering agents on acute renal allograft rejection
    • Kasiske BL, Heim-Duthoy KL, Singer GG, et al. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 2001; 12: 223-7.
    • (2001) Transplantation , vol.12 , pp. 223-227
    • Kasiske, B.L.1    Heim-Duthoy, K.L.2    Singer, G.G.3
  • 33
    • 33749040295 scopus 로고    scopus 로고
    • Breast cancer growth prevention by statins
    • Campbell MJ, Esserman LJ, Zhou Y, et al. Breast cancer growth prevention by statins. Cancer Res 2006; 66: 8707-14.
    • (2006) Cancer Res , vol.66 , pp. 8707-8714
    • Campbell, M.J.1    Esserman, L.J.2    Zhou, Y.3
  • 34
    • 33749577598 scopus 로고    scopus 로고
    • Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells
    • Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 2006, 5: 2310-6.
    • (2006) Mol Cancer Ther , vol.5 , pp. 2310-2316
    • Sivaprasad, U.1    Abbas, T.2    Dutta, A.3
  • 35
    • 0036014951 scopus 로고    scopus 로고
    • Immunomodulatory effects of statins: Mechanisms and potential impact on arteriosclerosis
    • Palinski W, Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002; 13: 1673-81.
    • (2002) J Am Soc Nephrol , vol.13 , pp. 1673-1681
    • Palinski, W.1    Tsimikas, S.2
  • 36
  • 37
    • 26844518501 scopus 로고    scopus 로고
    • Statins in nephrotic syndrome: A new weapon against tissue injury
    • Buemi M, Nostra L, Crasci E, et al. Statins in nephrotic syndrome: a new weapon against tissue injury. Med Res Rev 2005;25(6):587-609.
    • (2005) Med Res Rev , vol.25 , Issue.6 , pp. 587-609
    • Buemi, M.1    Nostra, L.2    Crasci, E.3
  • 38
    • 0038512398 scopus 로고    scopus 로고
    • Cholesterol and recurrent events trial investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease
    • Tonelly M, Moye L, Sacks FM, Cole T, Curhan GC. Cholesterol and recurrent events trial investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14: 1605-13.
    • (2003) J Am Soc Nephrol , vol.14 , pp. 1605-1613
    • Tonelly, M.1    Moye, L.2    Sacks, F.M.3    Cole, T.4    Curhan, G.C.5
  • 39
    • 0036092253 scopus 로고    scopus 로고
    • Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis
    • Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 2002; 17: 798-802.
    • (2002) Nephrol Dial Transplant , vol.17 , pp. 798-802
    • Nakamura, T.1    Ushiyama, C.2    Hirokawa, K.3
  • 40
    • 7244238435 scopus 로고    scopus 로고
    • Managing dyslipidemia in chronic kidney disease
    • Weiner DE, Sarank MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 2004; 19: 1045-52.
    • (2004) J Gen Intern Med , vol.19 , pp. 1045-1052
    • Weiner, D.E.1    Sarank, M.J.2
  • 41
    • 0038512398 scopus 로고    scopus 로고
    • Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease
    • Tonelly M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14: 1605-13.
    • (2003) J Am Soc Nephrol , vol.14 , pp. 1605-1613
    • Tonelly, M.1    Moye, L.2    Sacks, F.M.3    Cole, T.4    Curhan, G.C.5
  • 42
    • 4344656255 scopus 로고    scopus 로고
    • Statin induced proteinuria: Renal injury or renoprotection?
    • Agrawal R. Statin induced proteinuria: renal injury or renoprotection?. J Am Soc Nephrol 2004; 15: 2502.
    • (2004) J Am Soc Nephrol , vol.15 , pp. 2502
    • Agrawal, R.1
  • 43
    • 26244455871 scopus 로고    scopus 로고
    • HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways
    • Chen JC, Huang KC, Lin WW. HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways. Cell Signal 2006;18(1):32-9.
    • (2006) Cell Signal , vol.18 , Issue.1 , pp. 32-39
    • Chen, J.C.1    Huang, K.C.2    Lin, W.W.3
  • 44
    • 0033050559 scopus 로고    scopus 로고
    • Effect of simvastatin on proliferative nephritis and cell-cycle protein expression
    • Yoshimura A, Nemoto T, Segenoya Y, et al. Effect of simvastatin on proliferative nephritis and cell-cycle protein expression. Kidney Int 1999 (Suppl 7); S84-S7.
    • (1999) Kidney Int , Issue.SUPPL. 7
    • Yoshimura, A.1    Nemoto, T.2    Segenoya, Y.3
  • 45
    • 0030820468 scopus 로고    scopus 로고
    • Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated AP-1 dependent pathway
    • Vrtovsnik F, Couette S, Prie D, Lallemand D, Friedlander G. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated AP-1 dependent pathway. Kidney Int 1997; 52: 1016-27.
    • (1997) Kidney Int , vol.52 , pp. 1016-1027
    • Vrtovsnik, F.1    Couette, S.2    Prie, D.3    Lallemand, D.4    Friedlander, G.5
  • 46
    • 27744446645 scopus 로고    scopus 로고
    • Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway
    • Bussolati B, Deregibus MC, Fonsato V, et al. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 2005; 16: 1936-47.
    • (2005) J Am Soc Nephrol , vol.16 , pp. 1936-1947
    • Bussolati, B.1    Deregibus, M.C.2    Fonsato, V.3
  • 47
    • 4544297213 scopus 로고    scopus 로고
    • Causes and therapy of microinflammation in renal failure
    • Schindler R. Causes and therapy of microinflammation in renal failure. Nephrol Dial. Transplant 2004, 19 (suppl 5): v34-v40.
    • (2004) Nephrol Dial. Transplant , vol.19 , Issue.SUPPL. 5
    • Schindler, R.1
  • 48
    • 0036741488 scopus 로고    scopus 로고
    • Statins and renal function
    • Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 2002; 53(5):493-502.
    • (2002) Angiology , vol.53 , Issue.5 , pp. 493-502
    • Elisaf, M.1    Mikhailidis, D.P.2
  • 49
    • 33646519915 scopus 로고    scopus 로고
    • Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects
    • Yasuda H, Yuen PS, Hu X, Zhou H, Star RA. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int 2006; 69: 1535-42.
    • (2006) Kidney Int , vol.69 , pp. 1535-1542
    • Yasuda, H.1    Yuen, P.S.2    Hu, X.3    Zhou, H.4    Star, R.A.5
  • 50
    • 31544457088 scopus 로고    scopus 로고
    • Simvastatin protection against acute immune-mediated glomerulonephritis in mice
    • Christensen M, Su AW, Snyder RW, et al. Simvastatin protection against acute immune-mediated glomerulonephritis in mice. Kidney Int 2006, 69:457-63.
    • (2006) Kidney Int , vol.69 , pp. 457-463
    • Christensen, M.1    Su, A.W.2    Snyder, R.W.3
  • 51
    • 34247877630 scopus 로고    scopus 로고
    • Pravastatin inhibits carboxymethyllysine- induced monocyte chemoattractant protein 1 expression in podocytes via prevention of signalling events
    • GuL, Ni Z, Qian J, Tomino Y. Pravastatin inhibits carboxymethyllysine- induced monocyte chemoattractant protein 1 expression in podocytes via prevention of signalling events. Nephron. Exp Nephrol 2007; 106: 1-10.
    • (2007) Nephron. Exp Nephrol , vol.106 , pp. 1-10
    • Gu, L.1    Ni, Z.2    Qian, J.3    Tomino, Y.4
  • 52
    • 5644282762 scopus 로고    scopus 로고
    • Massy ZA, Andrejak M. The interest of statins in nephrology. Presse Med 2004 9;33(17):1207-12.
    • Massy ZA, Andrejak M. The interest of statins in nephrology. Presse Med 2004 9;33(17):1207-12.
  • 53
    • 0343114434 scopus 로고    scopus 로고
    • Lovastatin inhibits TGF-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cels
    • Kim SI, Han DC, Lee HB. Lovastatin inhibits TGF-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cels. J Am Soc Nephrol 2000; 11:80-7.
    • (2000) J Am Soc Nephrol , vol.11 , pp. 80-87
    • Kim, S.I.1    Han, D.C.2    Lee, H.B.3
  • 54
    • 20544474463 scopus 로고    scopus 로고
    • on behalf of the ALERT study group. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: Lessons to be learnt from the assessment of Lescol in renal transplantation (ALERT) trial
    • Holdaas H, Fellstrom B, Jardine AG; on behalf of the ALERT study group. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: lessons to be learnt from the assessment of Lescol in renal transplantation (ALERT) trial. Am J Transplant 2005;5(6):1574-5.
    • (2005) Am J Transplant , vol.5 , Issue.6 , pp. 1574-1575
    • Holdaas, H.1    Fellstrom, B.2    Jardine, A.G.3
  • 55
    • 31544440132 scopus 로고    scopus 로고
    • In vitro and in vivo effects of simvastatin on inflammatory markers in pre-dialysis patients
    • Panichi V, Paoletti S, Mantuano E, et al. In vitro and in vivo effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 2006; 21:337-44.
    • (2006) Nephrol Dial Transplant , vol.21 , pp. 337-344
    • Panichi, V.1    Paoletti, S.2    Mantuano, E.3
  • 56
    • 33745836406 scopus 로고    scopus 로고
    • Statins for improving renal outcomes: A meta-analysis
    • Sandhu S, Wiebe N, Fried LF, Tonelly M. Statins for improving renal outcomes: a meta-analysis J Am Soc Nephrol 2006; 17: 2006-16.
    • (2006) J Am Soc Nephrol , vol.17 , pp. 2006-2016
    • Sandhu, S.1    Wiebe, N.2    Fried, L.F.3    Tonelly, M.4
  • 57
    • 33845241489 scopus 로고    scopus 로고
    • Do statins have a beneficial effect on the kidney
    • Levi M. Do statins have a beneficial effect on the kidney. Nat Clin Practice Nephrology 2006; 2: 666-7.
    • (2006) Nat Clin Practice Nephrology , vol.2 , pp. 666-667
    • Levi, M.1
  • 59
    • 29444438428 scopus 로고    scopus 로고
    • Clinical implications for statin pleiotropy
    • Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005;16(6):624-9.
    • (2005) Curr Opin Lipidol , vol.16 , Issue.6 , pp. 624-629
    • Liao, J.K.1
  • 60
    • 0036150077 scopus 로고    scopus 로고
    • Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose
    • Chen HC, Guh JY, Shin SJ, Lai YH. Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. Atherosclerosis 2002; 160: 141-6.
    • (2002) Atherosclerosis , vol.160 , pp. 141-146
    • Chen, H.C.1    Guh, J.Y.2    Shin, S.J.3    Lai, Y.H.4
  • 61
    • 24944503596 scopus 로고    scopus 로고
    • Statins and stroke
    • Sep;
    • Endres M. Statins and stroke. J Cereb Blood Flow Metab. 2005 Sep;25(9):1093-110.
    • (2005) J Cereb Blood Flow Metab , vol.25 , Issue.9 , pp. 1093-1110
    • Endres, M.1
  • 63
    • 33847389770 scopus 로고    scopus 로고
    • Prevention and treatment of dementia or Alzheimer's disease by statins: A meta-analysis
    • Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Dement Geriatr Cogn Disord 2007;23(3):194-201.
    • (2007) Dement Geriatr Cogn Disord , vol.23 , Issue.3 , pp. 194-201
    • Zhou, B.1    Teramukai, S.2    Fukushima, M.3
  • 64
    • 47949117714 scopus 로고    scopus 로고
    • Sieff CA. Regulation of erythropoiesis. Up to Date 2006, 14.1.
    • Sieff CA. Regulation of erythropoiesis. Up to Date 2006, 14.1.
  • 65
    • 0027367661 scopus 로고
    • Identification of the renal erythropoietin- producing cells using transgenic mice
    • Maxwell PH, Osmond MK, Pugh CW, et al. Identification of the renal erythropoietin- producing cells using transgenic mice. Kidney Int 1993; 44: 1149.
    • (1993) Kidney Int , vol.44 , pp. 1149
    • Maxwell, P.H.1    Osmond, M.K.2    Pugh, C.W.3
  • 66
    • 0027935351 scopus 로고
    • Transgenic mice carrying the erythropoietin gene promoter linked to lacZ express the reporter in proximal convoluted tubule cells after hypoxia
    • Loya F, Yang Y, Lin H, et al. Transgenic mice carrying the erythropoietin gene promoter linked to lacZ express the reporter in proximal convoluted tubule cells after hypoxia. Blood 1994; 84: 1831.
    • (1994) Blood , vol.84 , pp. 1831
    • Loya, F.1    Yang, Y.2    Lin, H.3
  • 67
    • 0037300439 scopus 로고    scopus 로고
    • Pleiotropic functions of erythropoietin
    • Sasaki P. Pleiotropic functions of erythropoietin. Intern Med 2003; 42:142-9.
    • (2003) Intern Med , vol.42 , pp. 142-149
    • Sasaki, P.1
  • 68
    • 0034982679 scopus 로고    scopus 로고
    • The erythopoietin receptor
    • Mulcahy L. The erythopoietin receptor. Semin Oncol 2001; 28(Suppl8): 19-23.
    • (2001) Semin Oncol , vol.28 , Issue.SUPPL.8 , pp. 19-23
    • Mulcahy, L.1
  • 69
    • 0004168918 scopus 로고    scopus 로고
    • Physician Education: The Erythtopoietin receptor and signal transduction
    • Yoshimura A, Arai K. Physician Education: The Erythtopoietin receptor and signal transduction. Oncologic 1996; 1: 337-9.
    • (1996) Oncologic , vol.1 , pp. 337-339
    • Yoshimura, A.1    Arai, K.2
  • 70
    • 0034016974 scopus 로고    scopus 로고
    • Unraveling distinct intracellular signals that promote survival and proliferation: Study of erythropoietin, stem cell factor, and constitutive signaling in leukemic cells
    • Sawyer ST, Jacobs-Helber SM. Unraveling distinct intracellular signals that promote survival and proliferation: study of erythropoietin, stem cell factor, and constitutive signaling in leukemic cells. J Hematother Stem Cell Res 2000;9(1):21-9.
    • (2000) J Hematother Stem Cell Res , vol.9 , Issue.1 , pp. 21-29
    • Sawyer, S.T.1    Jacobs-Helber, S.M.2
  • 71
    • 1542286103 scopus 로고    scopus 로고
    • Erythropoietin in cardiovascular diseases
    • van der Meer P, Voors AA, Lipsic E, et al. Erythropoietin in cardiovascular diseases. Eur Heart J 2004; 25(4):285-91.
    • (2004) Eur Heart J , vol.25 , Issue.4 , pp. 285-291
    • van der Meer, P.1    Voors, A.A.2    Lipsic, E.3
  • 72
    • 4644310308 scopus 로고    scopus 로고
    • Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells
    • Beleslin-Cokic BB, Cokic VP, Yu X, et al. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004;104(7):2073-80.
    • (2004) Blood , vol.104 , Issue.7 , pp. 2073-2080
    • Beleslin-Cokic, B.B.1    Cokic, V.P.2    Yu, X.3
  • 73
    • 7444253390 scopus 로고    scopus 로고
    • Beneficial and ominous aspects of the pleiotropic action of erythropoietin
    • Jelkmann W., Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 2004; 83: 673-86.
    • (2004) Ann Hematol , vol.83 , pp. 673-686
    • Jelkmann, W.1    Wagner, K.2
  • 74
    • 0036455109 scopus 로고    scopus 로고
    • Epo's alter ego: Erythropoietin has multiple actions
    • Lappin TR, Maxwell P, Johnston PG. Epo's alter ego: erythropoietin has multiple actions. Stem Cells 2002; 20: 485-92.
    • (2002) Stem Cells , vol.20 , pp. 485-492
    • Lappin, T.R.1    Maxwell, P.2    Johnston, P.G.3
  • 75
    • 19444372033 scopus 로고    scopus 로고
    • Erythropoietin mimics ischemic preconditioning
    • Baker JE. Erythropoietin mimics ischemic preconditioning. Vascul Pharmacol 2005; 42(5-6):233-41.
    • (2005) Vascul Pharmacol , vol.42 , Issue.5-6 , pp. 233-241
    • Baker, J.E.1
  • 76
    • 33750847474 scopus 로고    scopus 로고
    • The interaction between heart failure and other heart diseases, renal failure and anemia
    • Silverberg DS, Wexler D, Iaina A, et al. The interaction between heart failure and other heart diseases, renal failure and anemia. Semin Nephrol 2006; 26:296-306.
    • (2006) Semin Nephrol , vol.26 , pp. 296-306
    • Silverberg, D.S.1    Wexler, D.2    Iaina, A.3
  • 78
    • 0033561341 scopus 로고    scopus 로고
    • Human erythropoietin induces a proangiogenic phenotype in cultured endothelial cells and stimulates neovascularisation in vivo
    • Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a proangiogenic phenotype in cultured endothelial cells and stimulates neovascularisation in vivo. Blood 1999, 93: 2627-36.
    • (1999) Blood , vol.93 , pp. 2627-2636
    • Ribatti, D.1    Presta, M.2    Vacca, A.3
  • 79
    • 0028901357 scopus 로고
    • Recombinant human erythropoietin stimulates angiogenesis in vitro
    • Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995; 47: 740-5.
    • (1995) Kidney Int , vol.47 , pp. 740-745
    • Carlini, R.G.1    Reyes, A.A.2    Rothstein, M.3
  • 80
    • 0028883849 scopus 로고
    • Effects of rHuEpo on cellular proliferation and endothelin-1 production in cultured endothelial cells
    • Nagai T, Akizawa T, Nakashima Y, et al. Effects of rHuEpo on cellular proliferation and endothelin-1 production in cultured endothelial cells. Nephrol Dial Transplant 1995; 10: 1814-9.
    • (1995) Nephrol Dial Transplant , vol.10 , pp. 1814-1819
    • Nagai, T.1    Akizawa, T.2    Nakashima, Y.3
  • 81
    • 0027274063 scopus 로고
    • Recombinant human erythropoietin (rHuEpo) increases endothelin-1 release by endothelial cells
    • Carlini RG, Dusso AS, Obialo CI, et al. Recombinant human erythropoietin (rHuEpo) increases endothelin-1 release by endothelial cells. Kidney Int 1993; 43: 1010-4.
    • (1993) Kidney Int , vol.43 , pp. 1010-1014
    • Carlini, R.G.1    Dusso, A.S.2    Obialo, C.I.3
  • 82
    • 34247853270 scopus 로고    scopus 로고
    • Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin
    • D'Uscio LV, Smith LA, Santham AV, et al. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 2007; 49: 1142-8.
    • (2007) Hypertension , vol.49 , pp. 1142-1148
    • D'Uscio, L.V.1    Smith, L.A.2    Santham, A.V.3
  • 83
    • 34447294258 scopus 로고    scopus 로고
    • Attenuation of inflammation and apoptosis by pre- and post treatment of darbepoetin alpha in acute liver failure of mice
    • Le Minh K, Klemm K, Abshagen K, et al. Attenuation of inflammation and apoptosis by pre- and post treatment of darbepoetin alpha in acute liver failure of mice. Am J Pathol 2007; 170:1954-63.
    • (2007) Am J Pathol , vol.170 , pp. 1954-1963
    • Le Minh, K.1    Klemm, K.2    Abshagen, K.3
  • 84
    • 34250630084 scopus 로고    scopus 로고
    • Erythropoietin induces heme oxygenase expression and attenuates oxidative stress
    • Katavetin P, Inaqi R, Miyata T, et al. Erythropoietin induces heme oxygenase expression and attenuates oxidative stress. Biochem Biophys Res Commun 2007; 359: 928-34.
    • (2007) Biochem Biophys Res Commun , vol.359 , pp. 928-934
    • Katavetin, P.1    Inaqi, R.2    Miyata, T.3
  • 86
    • 11244333356 scopus 로고    scopus 로고
    • New avenues of exploration for erythropoietin
    • Maiese K, Li F, Chong Z. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-5.
    • (2005) JAMA , vol.293 , pp. 90-95
    • Maiese, K.1    Li, F.2    Chong, Z.3
  • 87
    • 34250675699 scopus 로고    scopus 로고
    • Erythropoietin enhances immune response in mice
    • Katz O, Gil L, Lifshitz L, et al. Erythropoietin enhances immune response in mice. Eur J Immunol 2007; 37: 1584-93.
    • (2007) Eur J Immunol , vol.37 , pp. 1584-1593
    • Katz, O.1    Gil, L.2    Lifshitz, L.3
  • 88
    • 13844320400 scopus 로고    scopus 로고
    • A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury
    • Fiordaliso F, Chimenti S, Staszewsky L, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2005;102(6):2046-51.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , Issue.6 , pp. 2046-2051
    • Fiordaliso, F.1    Chimenti, S.2    Staszewsky, L.3
  • 89
    • 33846057722 scopus 로고    scopus 로고
    • Pleiotropic effects of erythropoietin in neuronal and vascular systems
    • Boogaerts M. Pleiotropic effects of erythropoietin in neuronal and vascular systems. Curr Med Res Opin 2006; 22 (Suppl 4):15-22.
    • (2006) Curr Med Res Opin , vol.22 , Issue.SUPPL. 4 , pp. 15-22
    • Boogaerts, M.1
  • 90
    • 6344225691 scopus 로고    scopus 로고
    • Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury
    • Wright GL, Hanlon P, Amin K, et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004;18(9):1031-3.
    • (2004) FASEB J , vol.18 , Issue.9 , pp. 1031-1033
    • Wright, G.L.1    Hanlon, P.2    Amin, K.3
  • 91
    • 33846188979 scopus 로고    scopus 로고
    • Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells
    • Prunier F, Pfister O, Hadri L, et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol. Heart Circ Physiol 2007; 292(1):H522-9.
    • (2007) Am J Physiol. Heart Circ Physiol , vol.292 , Issue.1
    • Prunier, F.1    Pfister, O.2    Hadri, L.3
  • 92
    • 20944439418 scopus 로고    scopus 로고
    • High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention
    • Namiuchi S, Kagoya Y, Ohta Y, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 45: 1406-12.
    • (2005) J Am Coll Cardiol , vol.45 , pp. 1406-1412
    • Namiuchi, S.1    Kagoya, Y.2    Ohta, Y.3
  • 93
    • 9144239992 scopus 로고    scopus 로고
    • Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial
    • Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004;15(1):148-56.
    • (2004) J Am Soc Nephrol , vol.15 , Issue.1 , pp. 148-156
    • Roger, S.D.1    McMahon, L.P.2    Clarkson, A.3
  • 94
    • 33847647055 scopus 로고    scopus 로고
    • Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial
    • Macdougall IC, Temple RM, Kwan JT. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrol Dial Transplant 2007;22(3):784-93.
    • (2007) Nephrol Dial Transplant , vol.22 , Issue.3 , pp. 784-793
    • Macdougall, I.C.1    Temple, R.M.2    Kwan, J.T.3
  • 95
    • 0035064310 scopus 로고    scopus 로고
    • Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture
    • Nagai A, Nakagawa E, Choi HB, et al. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001;60(4):386-92.
    • (2001) J Neuropathol Exp Neurol , vol.60 , Issue.4 , pp. 386-392
    • Nagai, A.1    Nakagawa, E.2    Choi, H.B.3
  • 97
    • 0036705708 scopus 로고    scopus 로고
    • Erythropoietin therapy for acute stroke is both safe and beneficial
    • Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8(8):495-505.
    • (2002) Mol Med , vol.8 , Issue.8 , pp. 495-505
    • Ehrenreich, H.1    Hasselblatt, M.2    Dembowski, C.3
  • 99
    • 17444398206 scopus 로고    scopus 로고
    • Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor
    • Viviani B, Bartesaghi S, Corsini E, et al. Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor. J Neurochem 2005;93(2):412-21.
    • (2005) J Neurochem , vol.93 , Issue.2 , pp. 412-421
    • Viviani, B.1    Bartesaghi, S.2    Corsini, E.3
  • 100
    • 0037339634 scopus 로고    scopus 로고
    • The pleiotropic effects of erythropoietin in central nervous system
    • Buemi M, Cavallaro E, Floccari F, et al. The pleiotropic effects of erythropoietin in central nervous system. J Neuropathol Exp Neurol 2003; 62: 228-36.
    • (2003) J Neuropathol Exp Neurol , vol.62 , pp. 228-236
    • Buemi, M.1    Cavallaro, E.2    Floccari, F.3
  • 101
    • 0037047154 scopus 로고    scopus 로고
    • Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma
    • Gorio A, Gokman N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002; 99: 9450-5.
    • (2002) Proc Natl Acad Sci USA , vol.99 , pp. 9450-9455
    • Gorio, A.1    Gokman, N.2    Erbayraktar, S.3
  • 102
    • 0036177399 scopus 로고    scopus 로고
    • A single subcutaneous bolus of erythropoietin nromalizaed cerbral blood floww autoregulation after subarachnoid haemorrhage in rats
    • Springborg JB, Ma X, Rochart P, et al. A single subcutaneous bolus of erythropoietin nromalizaed cerbral blood floww autoregulation after subarachnoid haemorrhage in rats. Br J Pharmacol 2002; 135: 823-9.
    • (2002) Br J Pharmacol , vol.135 , pp. 823-829
    • Springborg, J.B.1    Ma, X.2    Rochart, P.3
  • 103
    • 33646846617 scopus 로고    scopus 로고
    • The brain erythropoietin system and its potential for therapeutic exploitation in brain disease
    • Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol 2006; 18: 132-8.
    • (2006) J Neurosurg Anesthesiol , vol.18 , pp. 132-138
    • Hasselblatt, M.1    Ehrenreich, H.2    Siren, A.L.3
  • 104
    • 3042725549 scopus 로고    scopus 로고
    • Derivaties of erythropoietin that are tissue protective but not erythropoietic
    • Leist M, Ghezzi P, Grasso G, et al. Derivaties of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305:239-42.
    • (2004) Science , vol.305 , pp. 239-242
    • Leist, M.1    Ghezzi, P.2    Grasso, G.3
  • 105
    • 0036705708 scopus 로고    scopus 로고
    • Erythropoietin therapy for acute stroke is both safe and beneficial
    • Ehrenreich H, Hasselblatt M, Dembovski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495-505.
    • (2002) Mol Med , vol.8 , pp. 495-505
    • Ehrenreich, H.1    Hasselblatt, M.2    Dembovski, C.3
  • 106
    • 0033628606 scopus 로고    scopus 로고
    • Neurocognitive dysfunction in cancer patients
    • Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology (Huntington) 2000; 14: 75-9.
    • (2000) Oncology (Huntington) , vol.14 , pp. 75-79
    • Meyers, C.A.1
  • 107
    • 0036970594 scopus 로고    scopus 로고
    • Unexpected renal actions of erythropoietin
    • Westenfelder C. Unexpected renal actions of erythropoietin. Exp Nephrol 2002;10(5-6):294-8.
    • (2002) Exp Nephrol , vol.10 , Issue.5-6 , pp. 294-298
    • Westenfelder, C.1
  • 108
    • 31544472841 scopus 로고    scopus 로고
    • Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/ reperfusion model
    • Spandou E, Tsouchnikas I, Karkavelas G, et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/ reperfusion model. Nephrol Dial Transplant, 2006; 21:330-6.
    • (2006) Nephrol Dial Transplant , vol.21 , pp. 330-336
    • Spandou, E.1    Tsouchnikas, I.2    Karkavelas, G.3
  • 109
    • 33646696626 scopus 로고    scopus 로고
    • Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure
    • Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69:1806-13.
    • (2006) Kidney Int , vol.69 , pp. 1806-1813
    • Johnson, D.W.1    Pat, B.2    Vesey, D.A.3
  • 110
    • 1042292029 scopus 로고    scopus 로고
    • Erythropoietin protects against ischaemic acute renal injury
    • Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004;19(2):348-55.
    • (2004) Nephrol Dial Transplant , vol.19 , Issue.2 , pp. 348-355
    • Vesey, D.A.1    Cheung, C.2    Pat, B.3
  • 111
    • 20244390303 scopus 로고    scopus 로고
    • Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy
    • Lee SH, Li C, Lim SW, et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol 2005; 25(1):64-76.
    • (2005) Am J Nephrol , vol.25 , Issue.1 , pp. 64-76
    • Lee, S.H.1    Li, C.2    Lim, S.W.3
  • 112
    • 34547746055 scopus 로고    scopus 로고
    • Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo
    • Epub ahead of print
    • Logar CM, Brinkkoetter PT, Krofft RD et al. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007 [Epub ahead of print].
    • (2007) Kidney Int
    • Logar, C.M.1    Brinkkoetter, P.T.2    Krofft, R.D.3
  • 113
    • 27144517603 scopus 로고    scopus 로고
    • Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy
    • Park J, Gage BF, Vijayan A. Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy. Am J Kidney Dis 2005; 46(5): 791-8.
    • (2005) Am J Kidney Dis , vol.46 , Issue.5 , pp. 791-798
    • Park, J.1    Gage, B.F.2    Vijayan, A.3
  • 114
    • 9644283016 scopus 로고    scopus 로고
    • Hemoglobin targets for the anemia of chronic kidney disease: A meta- analysis of randomized controlled trials
    • Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta- analysis of randomized controlled trials. J Am Soc Nephrol 2004; 15: 3154.
    • (2004) J Am Soc Nephrol , vol.15 , pp. 3154
    • Strippoli, G.F.1    Craig, J.C.2    Manno, C.3    Schena, F.P.4
  • 116
    • 0025931994 scopus 로고
    • Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: A comparative analysis
    • Evans RW. Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: a comparative analysis. Am J Kidney Dis 1991;18(4 Suppl 1):62-70.
    • (1991) Am J Kidney Dis , vol.18 , Issue.4 SUPPL. 1 , pp. 62-70
    • Evans, R.W.1
  • 117
    • 0035147487 scopus 로고    scopus 로고
    • Use of erythropoietin before the initiation of dialysis and its impact on mortality
    • Feb;
    • Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001 Feb;37(2):348-55.
    • (2001) Am J Kidney Dis , vol.37 , Issue.2 , pp. 348-355
    • Fink, J.1    Blahut, S.2    Reddy, M.3    Light, P.4
  • 118
    • 34547702814 scopus 로고    scopus 로고
    • Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: A review of clinical data
    • Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Nephrol Dial Transplant 2007; 22 Suppl4: iv19-iv30.
    • (2007) Nephrol Dial Transplant , vol.22 , Issue.SUPPL.4
    • Carrera, F.1    Disney, A.2    Molina, M.3
  • 119
    • 20344390799 scopus 로고    scopus 로고
    • Therapy insight: Copngestive heart failure, chronic kidney disease and anemia, the cardioanemia renal syndrome
    • Iaina A, Silverberg DS, Wexley D. Therapy insight: copngestive heart failure, chronic kidney disease and anemia, the cardioanemia renal syndrome. Natl Clin Parct Cardiovasc Med 2005; 2: 95-100.
    • (2005) Natl Clin Parct Cardiovasc Med , vol.2 , pp. 95-100
    • Iaina, A.1    Silverberg, D.S.2    Wexley, D.3
  • 120
    • 33746526038 scopus 로고    scopus 로고
    • Anemia, chronic renal disease and congestive heart failure- the cardiorenal anemia syndrome: The need for cooperation between cardiologist and nephrologist
    • Silverberg DS, Wexley D, Iaina A, et al. Anemia, chronic renal disease and congestive heart failure- the cardiorenal anemia syndrome: the need for cooperation between cardiologist and nephrologist. Int Urol Nephrol 2006; 38: 295-310.
    • (2006) Int Urol Nephrol , vol.38 , pp. 295-310
    • Silverberg, D.S.1    Wexley, D.2    Iaina, A.3
  • 121
    • 33750957845 scopus 로고    scopus 로고
    • Erythropoietin and the cardiorenal syndrome: Cellular mechanisms on the cardiorenal connectors
    • Jie KE, Verhaar MC, Cramer MJ, et al. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 2006; 291(5): F932-F44.
    • (2006) Am J Physiol Renal Physiol , vol.291 , Issue.5
    • Jie, K.E.1    Verhaar, M.C.2    Cramer, M.J.3
  • 122
    • 0033210904 scopus 로고    scopus 로고
    • Statins and blockers of the renin-angiotensin system. Vascular protection beyond their primary mode of action
    • Faggiotto A, Paoletti R. Statins and blockers of the renin-angiotensin system. Vascular protection beyond their primary mode of action. Hypertension 1999; 34: 987-96.
    • (1999) Hypertension , vol.34 , pp. 987-996
    • Faggiotto, A.1    Paoletti, R.2
  • 123
    • 0036891829 scopus 로고    scopus 로고
    • How to fully protect the kidney in a severe model of progressive nephropathy: Multidrug approach
    • Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: multidrug approach. J Am Soc Nephrol 2002; 13: 2898-2908.
    • (2002) J Am Soc Nephrol , vol.13 , pp. 2898-2908
    • Zoja, C.1    Corna, D.2    Camozzi, D.3
  • 124
    • 0035683590 scopus 로고    scopus 로고
    • Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins
    • Gryglewski RJ, Uracz W, Swies J, et al. Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins. Am NY Acad Sci 2001; 947: 229-45.
    • (2001) Am NY Acad Sci , vol.947 , pp. 229-245
    • Gryglewski, R.J.1    Uracz, W.2    Swies, J.3
  • 125
    • 0036323450 scopus 로고    scopus 로고
    • Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress
    • Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 2002; 40: 142-7.
    • (2002) Hypertension , vol.40 , pp. 142-147
    • Delbosc, S.1    Cristol, J.P.2    Descomps, B.3    Mimran, A.4    Jover, B.5
  • 126
    • 3543035785 scopus 로고    scopus 로고
    • Simvastatin combined with ramipril treatment in hypercholesterolemic patients
    • Koh KK, Son JW, Ahn JY, et al. Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension 2004; 44: 180-5.
    • (2004) Hypertension , vol.44 , pp. 180-185
    • Koh, K.K.1    Son, J.W.2    Ahn, J.Y.3
  • 127
    • 20844456215 scopus 로고    scopus 로고
    • Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercolesterolemic , hypertensive patients
    • Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercolesterolemic , hypertensive patients. Circulation 2004; 110(24):3687-92.
    • (2004) Circulation , vol.110 , Issue.24 , pp. 3687-3692
    • Koh, K.K.1    Quon, M.J.2    Han, S.H.3
  • 128
    • 0036237855 scopus 로고    scopus 로고
    • Effect of combining ACE inhibitor and statin in severe experimental nephropathy
    • Zoja C, Corna D, Rottoli D, et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002; 61: 1635-45.
    • (2002) Kidney Int , vol.61 , pp. 1635-1645
    • Zoja, C.1    Corna, D.2    Rottoli, D.3
  • 129
    • 0027731267 scopus 로고
    • Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats
    • Lee SK, Jin SY, Han DC, Hwang SD, Lee HB. Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 1993;8(12):1338-43.
    • (1993) Nephrol Dial Transplant , vol.8 , Issue.12 , pp. 1338-1343
    • Lee, S.K.1    Jin, S.Y.2    Han, D.C.3    Hwang, S.D.4    Lee, H.B.5
  • 130
    • 34147125246 scopus 로고    scopus 로고
    • Atorvastatin inhibits angiotensin- converting enzyme induction in differentiating human macrophages
    • Saijonmaa O, Nyman T, Fyhrquist T. Atorvastatin inhibits angiotensin- converting enzyme induction in differentiating human macrophages. Am J Physiol Heart Circ Physiol 2007; 292: 1917-21.
    • (2007) Am J Physiol Heart Circ Physiol , vol.292 , pp. 1917-1921
    • Saijonmaa, O.1    Nyman, T.2    Fyhrquist, T.3
  • 131
    • 0031970298 scopus 로고    scopus 로고
    • High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients
    • Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-10.
    • (1998) Nephrol Dial Transplant , vol.13 , pp. 1206-1210
    • Albitar, S.1    Genin, R.2    Fen-Chong, M.3    Serveaux, M.O.4    Bourgeon, B.5
  • 132
    • 0027762096 scopus 로고
    • Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients?
    • Walter J. Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients? Nephrol DialTransplant 1994; 8: 1428-31.
    • (1994) Nephrol DialTransplant , vol.8 , pp. 1428-1431
    • Walter, J.1
  • 133
    • 0029911808 scopus 로고    scopus 로고
    • Hesse E, Sperschneider H, Stein G. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? Nephrol Dial Transplant 1996; 11: 749-51.
    • Hesse E, Sperschneider H, Stein G. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? Nephrol Dial Transplant 1996; 11: 749-51.
  • 134
    • 0028048584 scopus 로고
    • ACE inhibitors do not affect erythropoetin efficacy in haemodialysis patients
    • Conlon PJ, Albers F, Butterly D, Schwab SJ. ACE inhibitors do not affect erythropoetin efficacy in haemodialysis patients. Nephrol DialTransplant 1994; 9: 1358.
    • (1994) Nephrol DialTransplant , vol.9 , pp. 1358
    • Conlon, P.J.1    Albers, F.2    Butterly, D.3    Schwab, S.J.4
  • 135
    • 85120141453 scopus 로고    scopus 로고
    • Abu-.Alfa AK, Cruz DN, Perazella MA, Mahnensmith RL, Simon D, Bisa MJ. ACE inhibitors do not induce recombinat human erythropoietin resistance in haemodialysis patients. Am J Kidney Dis 2000; 35: 1076-82.
    • Abu-.Alfa AK, Cruz DN, Perazella MA, Mahnensmith RL, Simon D, Bisa MJ. ACE inhibitors do not induce recombinat human erythropoietin resistance in haemodialysis patients. Am J Kidney Dis 2000; 35: 1076-82.
  • 136
    • 0032787799 scopus 로고    scopus 로고
    • The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirment of haemodialysis patients
    • Chew CG, Weise MD, Disney APS. The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirment of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2047-9.
    • (1999) Nephrol Dial Transplant , vol.14 , pp. 2047-2049
    • Chew, C.G.1    Weise, M.D.2    Disney, A.P.S.3
  • 137
    • 29244476852 scopus 로고    scopus 로고
    • Anti-renin-angiotensin-system drugs and development of anemia in chronic kidney disease
    • Piccoli A, Pastori G, Pierobon E, et al. Anti-renin-angiotensin-system drugs and development of anemia in chronic kidney disease. J Nephrol 2005; 18: 585-91.
    • (2005) J Nephrol , vol.18 , pp. 585-591
    • Piccoli, A.1    Pastori, G.2    Pierobon, E.3
  • 138
    • 0029128155 scopus 로고
    • ACE inhibitors do not decrease rHuEPO response in patients with end - stage renal failure
    • Sanchez JA. ACE inhibitors do not decrease rHuEPO response in patients with end - stage renal failure. Nephrol Dial Transplant 1995; 10: 1476-7.
    • (1995) Nephrol Dial Transplant , vol.10 , pp. 1476-1477
    • Sanchez, J.A.1
  • 139
    • 0032917369 scopus 로고    scopus 로고
    • Angiotensin- converting enzyme inhibitors but not Angiotensin II AT1 receptors antagonist affect erythropoiesis in patients with anemia of end - stage renal disease
    • Schiff H, Lang SM. Angiotensin- converting enzyme inhibitors but not Angiotensin II AT1 receptors antagonist affect erythropoiesis in patients with anemia of end - stage renal disease. Nephron 1999;81:106-8.
    • (1999) Nephron , vol.81 , pp. 106-108
    • Schiff, H.1    Lang, S.M.2
  • 140
    • 33645692159 scopus 로고    scopus 로고
    • Angiotensin converting enzyme (ACE) and hydroxy methyl glutaryl- Coa (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium
    • 57: Suppl 86-96
    • Chlopicki S, Gryglewski R. Angiotensin converting enzyme (ACE) and hydroxy methyl glutaryl- Coa (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium. Pharmacological Reports 2006; 57: Suppl 86-96.
    • Pharmacological Reports 2006
    • Chlopicki, S.1    Gryglewski, R.2
  • 141
    • 33646033153 scopus 로고    scopus 로고
    • HMG-CoA reductase inhibitors induce apoptosis in pericytes
    • Boucher K, Siegel CS, Sharma P, et al. HMG-CoA reductase inhibitors induce apoptosis in pericytes. Microvasc Res 2006; 71: 91-102.
    • (2006) Microvasc Res , vol.71 , pp. 91-102
    • Boucher, K.1    Siegel, C.S.2    Sharma, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.